HomeNewsBusinessReal EstateRLDA to issue tenders worth Rs 10,000 crore for land redevelopment in FY21

RLDA to issue tenders worth Rs 10,000 crore for land redevelopment in FY21

It had issued tenders worth Rs 3,500 crore in 2019-20 and earned a revenue of Rs 931 crore

June 30, 2020 / 18:26 IST
Story continues below Advertisement
Representative image
Representative image

Despite the coronavirus pandemic, the Rail Land Development Authority (RLDA) a statutory authority under the ministry of railways responsible for the development of vacant railway land, is targeting to issue tenders worth Rs 10,000 crore in 2020-2021 and eyeing revenue of Rs 3,000 crore, top sources in RLDA said.

RLDA issued tenders worth Rs 3,500 crore during 2019-2020 and the total earnings was Rs 931 crore.

Story continues below Advertisement

"While our target is to issue tenders worth Rs 10,000 crore in 2020-21 against Rs 3,500 crore in the previous year, a  sum Rs 3,000 crore is expected from these prime plots. The plot in Kolkata alone is expected to generate Rs 800 crore as it is along a riverfront," said Ved Parkash Dudeja, vice chairman of RLDA.

The rest would be generated from prime commercial and residential plots located in Mumbai, Chennai, Hyderabad and Delhi.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show